

[Ethambutol + isoniazid](#)

Not recommended as an essential medicine

Section:

[6. Anti-infective medicines](#) [6.2. Antibacterials](#) [6.2.5. Antituberculosis medicines](#)

Codes ATC: [J04AM03](#)

Indication

Tuberculosis Code ICD11: [1B4Z](#)

INN

Ethambutol + isoniazid

Type de médicament

Chemical agent

Type de liste

Liste de base

Formulations

Oral > Solid: 400 mg + 150 mg tablet

Historique des statuts LME

Ajouté pour la première fois en 1997 ([TRS 882](#))

Retiré en 2019 ([TRS 1021](#))

Sexe

Tous

Âge

Adolescents et adultes

Équivalence thérapeutique

La recommandation concerne ce médicament spécifique

Renseignements sur le brevet

Patents have expired in most jurisdictions

Lire la suite [sur les brevets](#).

Wikipédia

[Ethambutol + isoniazid](#)

[DrugBank](#)

[Ethambutol](#),

[Isoniazid](#)

Résumé des preuves et recommandation du comité d'experts

The Expert Committee recommended the deletion of ethambutol + isoniazid (HE) fixed-dose combination formulation from the core list of the EML, noting the advice of the WHO Global TB Programme that its use is no longer recommended in current WHO guidelines based on evidence that treatment regimens involving this formulation have been associated with greater rates of relapses and death than alternative treatments. The 2010 WHO Treatment of tuberculosis guidelines for the treatment of tuberculosis (1) recommended that the two-month rifampicin regimen, 2HRZE/6HE, should be phased out, based on evidence that showed it to be associated with more relapses and deaths than the six-month rifampicin regimen, 2HRZE/4HR.